These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27331076)

  • 1. Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery.
    Fu H; Cataldi MP; Ware TA; Zaraspe K; Meadows AS; Murrey DA; McCarty DM
    Mol Ther Methods Clin Dev; 2016; 3():16036. PubMed ID: 27331076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
    Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector.
    Bobo TA; Samowitz PN; Robinson MI; Fu H
    Mol Ther Methods Clin Dev; 2020 Dec; 19():474-485. PubMed ID: 33313335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
    Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
    Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Root Cause by Systemic scAAV9-h
    Fu H; Zaraspe K; Murakami N; Meadows AS; Pineda RJ; McCarty DM; Muenzer J
    Mol Ther Methods Clin Dev; 2018 Sep; 10():327-340. PubMed ID: 30191159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.
    Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C
    Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains.
    Hocquemiller M; Hemsley KM; Douglass ML; Tamang SJ; Neumann D; King BM; Beard H; Trim PJ; Winner LK; Lau AA; Snel MF; Gomila C; Ausseil J; Mei X; Giersch L; Plavsic M; Laufer R
    Mol Ther Methods Clin Dev; 2020 Jun; 17():174-187. PubMed ID: 31909089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
    Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
    Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
    Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
    J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal Bone Marrow Transplantation in MPS IIIA Mice.
    Lau AA; Shamsani NJ; Winner LK; Hassiotis S; King BM; Hopwood JJ; Hemsley KM
    JIMD Rep; 2013; 8():121-32. PubMed ID: 23430528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
    Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
    Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
    Bosch ME; Aldrich A; Fallet R; Odvody J; Burkovetskaya M; Schuberth K; Fitzgerald JA; Foust KD; Kielian T
    J Neurosci; 2016 Sep; 36(37):9669-82. PubMed ID: 27629717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.
    McIntyre C; Derrick-Roberts AL; Byers S; Anson DS
    J Gene Med; 2014; 16(11-12):374-87. PubMed ID: 25418946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice.
    Fu H; Kang L; Jennings JS; Moy SS; Perez A; Dirosario J; McCarty DM; Muenzer J
    Gene Ther; 2007 Jul; 14(14):1065-77. PubMed ID: 17460717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
    Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
    Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors.
    Lau AA; Hopwood JJ; Kremer EJ; Hemsley KM
    Mol Genet Metab; 2010 Jun; 100(2):168-75. PubMed ID: 20231109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.
    Haurigot V; Marcó S; Ribera A; Garcia M; Ruzo A; Villacampa P; Ayuso E; Añor S; Andaluz A; Pineda M; García-Fructuoso G; Molas M; Maggioni L; Muñoz S; Motas S; Ruberte J; Mingozzi F; Pumarola M; Bosch F
    J Clin Invest; 2013 Aug; 123(8):3254-3271. PubMed ID: 23863627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.